Associated Papers
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
40200811 (PubMed )
Supplement: cbm-22-237-s001.pdf
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
39338204 (PubMed )
Supplement: jpm-14-00950-s001.zip › Supplementary_Table_S5.xlsx › Supplementary_Table_S5.
An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development.
Wang Q et al.
Journal of Cancer, 2024
38370388 (PubMed )
Supplement: jcav15p1687s1.zip › Supplementary_Materials › Clinical_and_Genomic_Data.xlsx › Gene_mutation
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
36430388 (PubMed )
Supplement: ijms-23-13898-s001.zip › ijms-1981646-supplementary.pdf
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
Adib E et al.
Genome Medicine, 2022
35428358 (PubMed )
Supplement: 13073_2022_1041_MOESM2_ESM.xlsx › S4_MET_Druggable
Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation.
Gao B et al.
Frontiers in Medicine, 2021
A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis".
Mi J et al.
Lung Cancer (amsterdam, Netherlands), 2020
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.
Yang H et al.
Lung Cancer (amsterdam, Netherlands), 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients.
Champagnac A et al.
Journal of Thoracic Disease, 2020
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Suzawa K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Select a paper to view details